Quintiles and DaVita Clinical Research Announce Strategic Alliance

Quintiles, a provider of product development and integrated healthcare services, and DaVita Clinical Research, a wholly-owned subsidiary of DaVita HealthCare Partners Inc., a provider of kidney care, have formed a global strategic alliance.

The alliance combines DaVita’s clinical care and expansive footprint of research sites with Quintiles’ operational delivery and therapeutic expertise in clinical trials.
 
“Through this alliance with DaVita Clinical Research, we will have the power to provide biopharmaceutical customers with nephrology expertise and global delivery capabilities to truly advance clinical research,” said Jeanne Hecht, senior vice president and global head, Site and Patient Networks at Quintiles. “Our aim is to align our processes to reduce cycle times and accelerate clinical trial execution. Moreover, we will be able to alleviate the burden on patients participating in renal disease trials by incorporating clinical research into clinical care.”
 
DaVita Clinical Research is part of DaVita Healthcare Partners, a leading provider of kidney care as well as one of the largest U.S. healthcare providers, providing care to more than 1 million patients who may be available for potential trial enrollment. DaVita Clinical Research brings to this alliance data-driven trial feasibility expertise, trial sites in Europe and Latin America, its clinical knowledge of renal patients as well as an established research infrastructure with DaVita dialysis facilities and 30 years’ experience conducting clinical trials across therapeutic areas.
 
With progressively complex protocol designs and the increasing demand for broad patient population participation, nephrology clinical studies can pose a series of challenges. Through this strategic alliance, the two companies align to provide capabilities and solutions for overcoming these challenges to deliver end-to-end support for renal disease clinical trials. By leveraging Quintiles’ protocol modeling and feasibility, in combination with DaVita’s extensive patient understanding, biopharmaceutical customers will be able to take advantage of the combined assets of both companies to progress their clinical programs.
 
“This alliance allows approaches to clinical development and clinical trial execution specifically in site identification, participant enrollment and study design,” said Amy Young, vice president and general manager of DaVita Clinical Research. “We are excited about the opportunities this affords our organizations to provide innovative solutions to the industry and the participants we serve.”
 
Quintiles helps healthcare companies improve their probability of success by connecting insights from scientific, therapeutic and analytics expertise with delivery for better outcomes. From advisory through operations, Quintiles provides product development and integrated healthcare services, including commercial and observational solutions. Conducting operations in approximately 100 countries, Quintiles is a member of the FORTUNE 500.
 
DaVita HealthCare Partners Inc., a Fortune 500 company, is the parent company of DaVita Kidney Care and HealthCare Partners. DaVita Kidney Care delivers dialysis services to patients with chronic kidney failure and end stage renal disease. As of March 31, DaVita Kidney Care operated or provided administrative services at 2,278 outpatient dialysis centers located in the United States serving approximately 180,000 patients. The company also operated 124 outpatient dialysis centers located in 10 countries outside the United States. HealthCare Partners manages and operates medical groups and affiliated physician networks in Arizona, California, Nevada, New Mexico, Florida, Colorado, and Washington. As of March 31, HealthCare Partners provided integrated care management for approximately 790,000 patients.
 
DaVita Clinical Research, a wholly owned subsidiary of DaVita HealthCare Partners Inc.,uses its applied database and real-world healthcare experience to assist pharmaceutical and medical device companies in the design, recruitment and completion of retrospective, prospective and pragmatic clinical trials. DCR’s scientific and clinical expertise spans the lifecycle of product development with more than 175 client companies. DCR’s Early Clinical Research unit (Phase I-IIa) and Late Phase Clinical Research (Phase IIb through post-marketing) network of physicians and investigative sites, Real World Healthcare Data, and Medical Communications are focused on providing research in both complex/specialty populations and therapeutic areas, and especially in CKD and ESRD populations.